We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00136552
First Posted: August 29, 2005
Last Update Posted: July 3, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Lymphoma Study Association
  Purpose
The purpose of this study is to assess in a prospective multicentric study (Phase III) the introduction of a monoclonal antibody directed against B-cells associated with a standard therapy including chemotherapy and alpha-interferon in first line treatment of patients with a large tumor burden follicular lymphoma.

Condition Intervention Phase
Lymphoma Drug: rituximab Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden

Resource links provided by NLM:


Further study details as provided by Lymphoma Study Association:

Primary Outcome Measures:
  • Event free survival

Secondary Outcome Measures:
  • Response rate
  • Overall survival

Estimated Enrollment: 360
Study Start Date: May 2000
Estimated Study Completion Date: December 2004
Detailed Description:

Follicular lymphoma patients with a large tumor burden will be randomized for 18 months of treatment with either:

  • Arm A: CHVP + alpha2a-interferon. Patients will receive 12 courses of CHVP (cyclophosphamide 600 mg/m², adriamycin 25 mg/m², etoposide 100 mg/m² on day 1 and prednisolone 40 mg/m² for 5 days), one course every month for 6 months then one course every other month for 12 additional months associated with alpha2a-interferon 4.5 millions units sub-cutaneously three times a week for 18 months.
  • Arm B: CHVP + alpha2a-interferon + rituximab. Patients will receive 6 monthly courses of CHVP (cyclophosphamide 600 mg/m², adriamycin 25 mg/m², etoposide 100 mg/m² on day 1 and prednisolone 40 mg/m² for 5 days) associated with 6 infusions of rituximab (375 mg/m2) associated with alpha2a-interferon 4.5 millions units sub-cutaneously three times a week for 18 months.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed follicular lymphoma with a biopsy performed in the last 3 months
  • Patients previously untreated.
  • Patients with at least one of the following symptoms requiring initiation of treatment:

    • Bulky disease at study entry according to the Groupe d'Etudes Lymphomes Folliculare (GELF) criteria: nodal or extranodal mass > 7cm in its greater diameter
    • B symptoms
    • Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 1
    • Elevated serum lactate dehydrogenase (LDH) or beta2-microglobulin
    • Involvement of at least 3 nodal sites (each with a diameter greater than 3 cm)
    • Symptomatic splenic enlargement
    • Compressive syndrome
    • Pleural/peritoneal effusion
  • Age must be > 18 years and less than 76 years
  • Having previously signed a written informed consent form.

Exclusion Criteria:

  • Transformation to high-grade lymphoma (secondary to “low-grade” follicular lymphoma).
  • Patients without a large tumor burden.
  • Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer.
  • Poor renal function: Serum creatinine > 150 μmol/L,
  • Known HIV infection or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  • Patients with contra-indication to interferon, adriamycin, or rituximab.
  • Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease). Judgment is up to the investigator.
  • Known sensitivity or allergy to murine products
  • Adult patient under tutelage.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00136552


Locations
Belgium
Groupe d'Etude des Lymphomes de l'adulte
Mont-Godinne, Belgium
France
Hôpital Henri Mondor
Créteil, France, 94010
Hôpital Saint Louis
Paris, France, 75010
Service d'Hématologie - Centre Hospitalier Lyon-Sud
Pierre-Bénite cedex, France, 69495
Centre Henri Becquerel
Rouen, France, 76038
Sponsors and Collaborators
Lymphoma Study Association
Investigators
Principal Investigator: Gilles A Salles, MD PhD Lymphoma Study Association
  More Information

Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00136552     History of Changes
Other Study ID Numbers: FL2000
PHRC
First Submitted: August 25, 2005
First Posted: August 29, 2005
Last Update Posted: July 3, 2007
Last Verified: July 2007

Keywords provided by Lymphoma Study Association:
lymphoma
follicular
B-cell
rituximab
interferon

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Follicular
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Rituximab
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents